Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CSB-001
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 11, 2024
Lead Product(s) : CSB-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oremepermin Alpha
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Organovo Holdings
Deal Size : $57.0 million
Deal Type : Series A Financing
Claris Bio Prepares for Next Stage with New Investor and Late-Stage Data in 2024
Details : The net proceeds will be used to advance CSB-001 (oremepermin alfa), a topical ocular biologic solution of dHGF, targets complete healing of the cornea surface in eyes with Neurotrophic Keratopathy.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Oremepermin Alpha
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Organovo Holdings
Deal Size : $57.0 million
Deal Type : Series A Financing
Lead Product(s) : CSB-001
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 13, 2024
Lead Product(s) : CSB-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CSB-001
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 01, 2021
Lead Product(s) : CSB-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable